Research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the stock.
TherapeuticsMD Stock Performance
Shares of TXMD stock opened at $1.61 on Friday. TherapeuticsMD has a fifty-two week low of $1.61 and a fifty-two week high of $4.35. The stock’s 50-day simple moving average is $2.00 and its 200-day simple moving average is $2.18.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $0.31 million during the quarter.
Institutional Investors Weigh In On TherapeuticsMD
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- How to Buy Cheap Stocks Step by Step
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- MarketBeat Week in Review – 6/24 – 6/28
- Are Penny Stocks a Good Fit for Your Portfolio?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.